-+ 0.00%
-+ 0.00%
-+ 0.00%

HCW Biologics targets 1H 2027 IND filing for pancreatic cancer T-cell engager HCW11-018b

PUBT·04/27/2026 11:31:45
Listen to the news
HCW Biologics targets 1H 2027 IND filing for pancreatic cancer T-cell engager HCW11-018b
  • HCW Biologics disclosed new preclinical findings for lead T-cell engager candidate HCW11-018b, targeting solid tumors with initial focus on pancreatic cancer.
  • Results were presented at AACR Annual Meeting 2026, outlining a mechanism intended to activate the therapy primarily within tumor microenvironment.
  • Data showed HCW11-018b penetrated tumor tissue, drove tumor shrinkage, reduced spread in animal models.
  • Company expects to file an IND application in first half of 2027 to seek authorization to start a clinical study in pancreatic cancer patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270730PRIMZONEFULLFEED9707178) on April 27, 2026, and is solely responsible for the information contained therein.